Determination of the optimal time for tamoxifen treatment in combination with radiotherapy

Jang,Hyunsoo; Baek,Junyoung; Nam,Kyung-Soo; Kim,Soyoung

doi:10.3892/ijo.2016.3687

Determination of the optimal time for tamoxifen treatment in combination with radiotherapy

Authors:
- Hyunsoo Jang
- Junyoung Baek
- Kyung-Soo Nam
- Soyoung Kim
View Affiliations

Affiliations: Department of Radiation Oncology, School of Medicine, Dongguk University, Gyeongju, Gyeongsangbuk-do 780-350, Republic of Korea, Department of Pharmacology, School of Medicine, Dongguk University, Gyeongju, Gyeongsangbuk-do 780-350, Republic of Korea
Published online on: September 9, 2016 https://doi.org/10.3892/ijo.2016.3687
Pages: 2147-2154

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although radiotherapy and tamoxifen have been extensively used to treat estrogen receptor α (ERα)-positive breast cancers, it is still questionable when tamoxifen should be started to maximize clinical benefits in combination with radiotherapy. Generally, clinician's opinion and experience are major determinants in scheduling concurrent or sequential tamoxifen and radiotherapy. Thus, we attempted to determine an optimal time to start tamoxifen treatment by analyzing tamoxifen responses at different times after irradiating MCF-7 cells to cumulative doses of 10 or 20-30 Gy. MCF-7 cells were irradiated with 5 Gy a week, twice (a cumulative dose of 10 Gy) followed by a period of recovery. MTT viability assay for tamoxifen was done with MCF-7 cells harvested immediately after each 5 Gy (MCF-7-5 Gy) or 10 Gy (MCF-7-10 Gy) irradiation or after subsequent culture of surviving MCF-7-10 Gy cells for 40 days (MCF-7-R1). To establish the radioresistant cells, the above cycles of irradiation were repeated for a cumulative dose of 20 Gy (MCF-7-R2) or 30 Gy (MCF-7-R3). In addition, cytotoxic effects of tamoxifen were also measured. Attenuated tamoxifen response was observed in MCF-7-5 Gy and 10 Gy cells, whereas the efficacy of tamoxifen was restored in MCF-7-R1 cells. Furthermore, these responses to tamoxifen correlated with ERα expression. However, the radioresistant MCF-7 cells (MCF-7-R2/R3) exhibited resistance to tamoxifen without change in ER expression, but the phosphorylation of AKT was increased. Taken together, our data suggest that sequential tamoxifen treatment following radiotherapy is more effective than concurrent treatment. Furthermore, the reduced efficacy of tamoxifen on radioresistant cells indicates that an additional targeted therapy, such as AKT inhibitor treatment, is required to improve tamoxifen response in radioresistant breast cancer.

View Figures

View References

1	National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. 2014, http://www.nccn.org.
2	Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, et al: Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: Risk factors and impact on distant metastases. Cancer. 106:35–41. 2006. View Article : Google Scholar
3	Arriagada R, Lê MG, Contesso G, Guinebretière JM, Rochard F and Spielmann M: Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 13:1404–1413. 2002. View Article : Google Scholar : PubMed/NCBI
4	Ha B, Suh HS, Lee J, Lee KJ, Lee R and Moon BI: Long-term results of forward intensity-modulated radiation therapy for patients with early-stage breast cancer. Radiat Oncol J. 31:191–198. 2013. View Article : Google Scholar
5	Masood S: Estrogen and progesterone receptors in cytology: A comprehensive review. Diagn Cytopathol. 8:475–491. 1992. View Article : Google Scholar : PubMed/NCBI
6	Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
7	Fisher B, Dignam J, Bryant J and Wolmark N: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 93:684–690. 2001. View Article : Google Scholar : PubMed/NCBI
8	Azria D, Pelegrin A, Dubois JB, Mirimanoff RO and Ozsahin M: Radiation therapy and tamoxifen: concurrent or sequential? It's no longer the question! J Clin Oncol. 23:4239–4241; author reply 4241–4232. 2005. View Article : Google Scholar : PubMed/NCBI
9	Harris EE, Christensen VJ, Hwang WT, Fox K and Solin LJ: Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol. 23:11–16. 2005. View Article : Google Scholar
10	Whelan T and Levine M: Radiation therapy and tamoxifen: Concurrent or sequential? That is the question. J Clin Oncol. 23:1–4. 2005. View Article : Google Scholar
11	Osborne CK, Boldt DH, Clark GM and Trent JM: Effects of tamoxifen on human breast cancer cell cycle kinetics: Accumulation of cells in early G1 phase. Cancer Res. 43:3583–3585. 1983.PubMed/NCBI
12	Paulsen GH, Strickert T, Marthinsen AB and Lundgren S: Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol. 35:1011–1019. 1996. View Article : Google Scholar : PubMed/NCBI
13	Wazer DE, Tercilla OF, Lin PS and Schmidt-Ullrich R: Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br J Radiol. 62:1079–1083. 1989. View Article : Google Scholar : PubMed/NCBI
14	Bentzen SM, Skoczylas JZ, Overgaard M and Overgaard J: Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 88:918–922. 1996. View Article : Google Scholar : PubMed/NCBI
15	Koc M, Polat P and Suma S: Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 64:171–175. 2002. View Article : Google Scholar : PubMed/NCBI
16	Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, et al: Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer. 72:608–613. 1997. View Article : Google Scholar : PubMed/NCBI
17	Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B and Haffty BG: Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol. 23:17–23. 2005. View Article : Google Scholar
18	Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK and Albain KS: Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 23:24–29. 2005. View Article : Google Scholar
19	Chun SY, Kwon YS, Nam KS and Kim S: Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters. Biomed Pharmacother. 72:37–43. 2015. View Article : Google Scholar : PubMed/NCBI
20	Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935. 2004. View Article : Google Scholar : PubMed/NCBI
21	Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC and Bender JR: Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 87:677–682. 2000. View Article : Google Scholar : PubMed/NCBI
22	Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 80:239–256. 2002. View Article : Google Scholar : PubMed/NCBI
23	Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1491–1494. 1995. View Article : Google Scholar : PubMed/NCBI
24	Rupnow BA and Knox SJ: The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis. 4:115–143. 1999. View Article : Google Scholar
25	Verheij M: Clinical biomarkers and imaging for radiotherapy-induced cell death. Cancer Metastasis Rev. 27:471–480. 2008. View Article : Google Scholar : PubMed/NCBI
26	Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L and Kroemer G: Cell death modalities: Classification and pathophysiological implications. Cell Death Differ. 14:1237–1243. 2007. View Article : Google Scholar : PubMed/NCBI
27	Eriksson D, Löfroth PO, Johansson L, Riklund KA and Stigbrand T: Cell cycle disturbances and mitotic catastrophes in HeLa Hep2 cells following 2.5 to 10 Gy of ionizing radiation. Clin Cancer Res. 13:S5501–S5508. 2007. View Article : Google Scholar
28	Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, et al: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
29	Lee HJ, Choe G, Jheon S, Sung SW, Lee CT and Chung JH: CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: A retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol. 5:649–657. 2010. View Article : Google Scholar : PubMed/NCBI
30	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
31	Ahmed KM, Dong S, Fan M and Li JJ: Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res. 4:945–955. 2006. View Article : Google Scholar : PubMed/NCBI
32	Kunigal S, Lakka SS, Joseph P, Estes N and Rao JS: Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res. 14:3617–3626. 2008. View Article : Google Scholar : PubMed/NCBI
33	Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, et al: HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res. 18:6634–6647. 2012. View Article : Google Scholar : PubMed/NCBI
34	No M, Choi EJ and Kim IA: Targeting HER2 signaling pathway for radiosensitization: Alternative strategy for therapeutic resistance. Cancer Biol Ther. 8:2351–2361. 2009. View Article : Google Scholar : PubMed/NCBI
35	Lin F, Luo J, Gao W, Wu J, Shao Z, Wang Z, Meng J, Ou Z and Yang G: COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol. 34:2817–2826. 2013. View Article : Google Scholar : PubMed/NCBI
36	Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 4:e8752013. View Article : Google Scholar : PubMed/NCBI
37	Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 1:707–717. 2002.PubMed/NCBI
38	Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D, Li XP and Tang JM: 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol. 99:9–18. 2006. View Article : Google Scholar : PubMed/NCBI